Natera, Inc. Company Profile

21:36 EDT 24th September 2018 | BioPortfolio

Natera is a genetic testing company that has developed a proprietary bioinformatics technology (Parental Support) to deliver accurate and comprehensive high throughput testing for reproductive indications from tiny quantities of DNA – as small as that from a single cell. Natera operates a CLIA laboratory in Redwood City, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include preimplantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an IVF cycle in order to select embryos with the highest probability of becoming healthy children; products of conception testing following miscarriage to rapidly and extensively analyze fetal chromosomes in order to understand the cause; and non-invasive prenatal testing to determine paternity or detect genetic disease by analyzing fragments of fetal DNA in a pregnant mother’s blood drawn in the first trimester. Non-invasive testing for paternity is currently available worldwide. Natera's clinical trial for non-invasive detection of chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. For more information, visit

News Articles [30 Associated News Articles listed on BioPortfolio]

Natera nets $84.6mm through FOPO

Prenatal genetic testing firm Natera Inc. netted $84.6mm in a public offering of 4.5mm shares at $20. The company will use the proceeds to further R&D existing technology, advance product offerings, a...

Natera Inc. Announces Fourth Quarter and Fiscal 2017 Earnings Conference Call

Natera CEO Matthew Rabinowitzis also scheduled to present at the 38 thAnnual Cowen Healthcare Conference in Bostonon March 14, 2018at 7:40 Read more...

Natera, Inc. Announces Second Quarter 2018 Earnings Conference Call

SAN CARLOS, Calif., Aug. 1, 2018 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, Read more...

Natera and Fox Chase Cancer Center to Collaborate on Kidney Cancer Study

SAN CARLOS, Calif., Aug. 15, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has partnered with Fox Chase Cancer Read more...

Natera Names Paul Billings Chief Medical Officer

Paul Billings has been named chief medical officer and senior vice president of medical affairs of Natera (NASDAQ: NTRA). Billings’ experience includes serving as chief medical officer of Life Techn...

QIAGEN und Natera kooperieren bei der Entwicklung hochmoderner genetischer Tests für den Einsatz auf QIAGENs GeneReader NGS-System

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) einem weltweit führenden Anbieter von Sample to Insight Lösungen, und Natera, Inc. (NASDAQ: NTRA) ein führender Entwickler von Next-Generati....

Natera and Institut Jules Bordet partner on breast cancer research

Genetic testing company Natera has partnered with the Belgian Institut Jules Bordet to advance breast cancer research. The collaboration will...Read More... The post Natera and Institut Jules Bordet p...

Natera and Bristol-Myers Squibb Partner to Investigate Signatera ctDNA Assay as a Potential Biomarker for Opdivo in a NSCLC Clinical Trial

SAN CARLOS, Calif., Sept. 13, 2018 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an agreement with Bristol-Myers Squibb to use Natera&...

Drugs and Medications [0 Results]


Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer

Natera is recruiting patients for a research study evaluating pregnancy and implantation rates in women undergoing In Vitro Fertilization (IVF) and Preimplantation Genetic Screening (PGS)....

Natera Ovarian Cancer Detection Assay

The purpose of this study is to collect blood, tissue, and health information from individuals with adnexal masses to develop a blood test to detect ovarian cancer.

Companies [2 Associated Companies listed on BioPortfolio]

Natera Inc.

Natera Inc. is a genetic testing company that specializes in analyzing microscopic quantities of DNA for reproductive health indications. The mission of the company is to help fam...

Natera, Inc.

Natera is a genetic testing company that has developed a proprietary bioinformatics technology (Parental Support) to deliver accurate and comprehensive high throughput testing for...

More Information about "Natera, Inc." on BioPortfolio

We have published hundreds of Natera, Inc. news stories on BioPortfolio along with dozens of Natera, Inc. Clinical Trials and PubMed Articles about Natera, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Natera, Inc. Companies in our database. You can also find out about relevant Natera, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Corporate Database Quicklinks

Searches Linking to this Company Record